Launching in Q4 / 2026

Invest in the revolution of non‑invasive brain monitoring

We are advancing a technology that addresses one of the most critical gaps in neurocritical care - and opens access to a market with multi-billion-dollar potential, driven by demographics, trauma incidence and the need for safer, earlier decision-making.

As we progress toward CE marking and market introduction, we are actively engaging with investors and strategic partners who want to shape this next chapter of non-invasive intracranial pressure assessment.
We invite you to engage with us - and explore what we could unlock together.

Create value. Save lives.

Investing in Sonovum means contributing to a future where critical brain assessment becomes safer, faster and accessible to far more patients than today. By enabling earlier insight without invasive risks, our technology addresses a significant clinical need in a global, high-value market.

Those who invest in us help unlock both measurable economic value and meaningful impact for patients and healthcare systems worldwide.

Compelling Market Opportunity

Differentiating Technology Platform

Capital-Efficient Execution

Meaningful Clinical Impact

Let's shape the future together

We would be pleased to discuss how we are advancing non-invasive intracranial pressure assessment - and how a partnership with the right investors can create meaningful clinical and economic value.

If our vision resonates with you, we warmly invite you to reach out to us and explore what we could achieve together.

Bertram König

CEO

Manuela Franke

CFO
Revolution of ICP
AI-driven brain diagnostics you can trust. Making brain monitoring simple, fast, and clinically meaningful.
Subscribe to our newsletter
© 2025 Sonovum. All rights reserved.